Benitec Biopharma (BNTC) Price & Analysis

Compare

281 Followers

BNTC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.06 - $17.15

Previous CloseN/A

Volume10.71K

Average Volume (3M)148.25K

Market Cap

$309.76M

Enterprise Value$399.49M

Total Cash (Recent Filing)$103.58M

Total Debt (Recent Filing)$959.00K

Price to Earnings (P/E)―

Beta0.44

Next Earnings

Sep 25, 2025

EPS Estimate

-0.29

Last Dividend Ex-Date

Jun 01, 2018

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.24

Shares Outstanding26,250,470

10 Day Avg. Volume52,077

30 Day Avg. Volume148,247

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.29

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.39K

Enterprise Value/Ebitda-13.34

Forecast

1Y Price Target

$22.10

Price Target Upside87.29% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical TrialsBB-301's Phase 1/2 clinical data showed significant improvements in dysphagia measures for OPMD patients, indicating promising therapeutic potential.

Financial PerformanceBenitec Biopharma reported a net loss of only $0.24 per share, beating the forecasted net loss of $0.36 per share, reflecting better-than-expected financial performance.

Funding And Cash ReservesBenitec Biopharma ended the period with $103.6 million in cash and equivalents, providing sufficient funding to support operations for the next 18 to 24 months.

Bears Say

Clinical Trial RisksRisks include slower-than-expected progress in the ongoing clinical trial of BB-301 and the potential for emergence of unexpected side effects.

Stock OfferingThe secondary offering is priced at $13 per share, which may lead to shareholder dilution.

Benitec Biopharma News

Analysts See Massive Upside in These 3 Russell 2000 Stocks

Small-cap stocks often fly under the radar, but some are now drawing attention from Wall Street. Analysts have...

23d ago

INR

BNTC

Benitec Biopharma management to meet virtually with Piper Sandler

Virtual Meeting to be held on July 14 hosted by Piper Sandler. Published first on TheFly – the...

1M ago

BNTC

Benitec Biopharma Advances BB-301 Clinical Study

Benitec Biopharma ( ($BNTC) ) has provided an update. On July 9, 2025, Benitec Biopharma announced that the...

1M ago

BNTC

Benitec reports DSMB recommendation to continue enrollment of Phase 1b/2a study

Benitec Biopharma (BNTC) announced the recommendation of the independent Data Safety Monitoring Board to continue enrollment of the...

1M ago

BNTC

Benitec Biopharma initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Benitec Biopharma (BNTC) with a Buy rating and no price target The company’s...

1M ago

BNTC

Innovative Gene Therapy Approach Drives Buy Rating for Benitec Biopharma

Ritu Baral, an analyst from TD Cowen, has initiated a new Buy rating on Benitec Biopharma (BNTC). Ritu...

1M ago

BNTC

Benitec Biopharma files to sell 900K shares of common stock for holders

17:13 EDT Benitec Biopharma (BNTC) files to sell 900K shares of common stock for holders Published first on...

3M ago

BNTC

Positive Buy Recommendation for Benitec Biopharma Driven by Promising Clinical Progress and Strong Financial Position

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Benitec Biopharma (BNTC – Research Report), retaining...

3M ago

BNTC

Benitec Biopharma reports Q3 EPS (24c) vs. (23c) last year

“We are profoundly honored to be closely engaged with the OPMD patient community and are thankful for the...

3M ago

BNTC

Benitec Biopharma price target raised to $20 from $18 at Citizens JMP

Citizens JMP raised the firm’s price target on Benitec Biopharma (BNTC) to $20 from $18 and keeps an...

4M ago

BNTC

Promising Clinical Results and Financial Stability Drive Buy Rating for Benitec Biopharma

Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Benitec Biopharma (BNTC – Research Report), boosting...

4M ago

BNTC

new option listings on April 9th

New option listings for April 9th include Alumis Inc (ALMS), LEVERAGE SHARES 2X LONG ASML DAILY ETF (ASMG),...

4M ago

LIF

MBX

Benitec Biopharma participates in a conference call with Cantor Fitzgerald

Cantor Fitzgerald holds a conference call with Chairman & CEO Banks on April 7 at 2 pm. Webcast...

4M ago

BNTC

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

APRE

BCDA

BNTC FAQ

What was Benitec Biopharma Ltd’s price range in the past 12 months?

Benitec Biopharma Ltd lowest stock price was $8.06 and its highest was $17.15 in the past 12 months.

What is Benitec Biopharma Ltd’s market cap?

Benitec Biopharma Ltd’s market cap is $309.76M.

When is Benitec Biopharma Ltd’s upcoming earnings report date?

Benitec Biopharma Ltd’s upcoming earnings report date is Sep 25, 2025 which is in 45 days.

How were Benitec Biopharma Ltd’s earnings last quarter?

Benitec Biopharma Ltd released its earnings results on May 14, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.348 by $0.108.

Is Benitec Biopharma Ltd overvalued?

According to Wall Street analysts Benitec Biopharma Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Benitec Biopharma Ltd pay dividends?

Benitec Biopharma Ltd pays a Notavailable dividend of $0.765 which represents an annual dividend yield of N/A. See more information on Benitec Biopharma Ltd dividends here

What is Benitec Biopharma Ltd’s EPS estimate?

Benitec Biopharma Ltd’s EPS estimate is -0.29.

How many shares outstanding does Benitec Biopharma Ltd have?

Benitec Biopharma Ltd has 26,250,470 shares outstanding.

What happened to Benitec Biopharma Ltd’s price movement after its last earnings report?

Benitec Biopharma Ltd reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.348. Following the earnings report the stock price went up 3.035%.

Which hedge fund is a major shareholder of Benitec Biopharma Ltd?

Currently, no hedge funds are holding shares in BNTC

Benitec Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-48.57%

Trailing 12-Months

Asset Growth

601.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Benitec Biopharma Ltd

Benitec Biopharma (BNTC) is a biotechnology company focused on developing therapeutic solutions using its proprietary DNA-directed RNA interference (ddRNAi) technology. This technology aims to silence disease-causing genes, offering a novel approach to treating a range of genetic disorders. The company's core focus areas include orphan diseases, infectious diseases, and oncology.

Benitec Biopharma (BNTC) Earnings & Revenues

Historic Earnings Reports

BNTC Stock 12 Month Forecast

Average Price Target

$22.10

▲(87.29% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","31":"$31","12.25":"$12.25","18.5":"$18.5","24.75":"$24.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,12.25,18.5,24.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.11,13.486153846153845,14.862307692307692,16.23846153846154,17.614615384615384,18.99076923076923,20.36692307692308,21.743076923076924,23.119230769230768,24.495384615384616,25.871538461538464,27.247692307692308,28.623846153846156,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.11,12.878461538461538,13.646923076923077,14.415384615384616,15.183846153846154,15.952307692307693,16.720769230769232,17.48923076923077,18.25769230769231,19.026153846153846,19.794615384615387,20.563076923076924,21.331538461538464,{"y":22.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.11,12.139999999999999,12.17,12.2,12.23,12.26,12.29,12.32,12.35,12.379999999999999,12.41,12.44,12.47,{"y":12.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.65,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.24,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.76,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.63,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.41,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.61,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >